

COVID-19 vaccine



Pfizer/biontech



Vaccine name : Pfizer-BioNTech COVID-19 Vaccine (BNT162b2/COMIRNATY Tozinameran (INN))

Vaccine type : Nucleoside modified mRNA



Technology used : nucleoside-modification of messenger RNA (modRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2 formulated in lipid particles.

Country of origin : USA



Date of approval by WHO : 31/12/2020

Doses and schedule : 2-dose series separated by 21 days*

A series started with COVID-19 vaccine (Pfizer) should be completed with this product

* Moderately to severely immunocompromised people: Consider an additional dose at least 28 days after the initial 2-dose primary series.

Efficacy & studies

Pfizer's the vaccine had 91.3% efficacy against COVID-19, based on measuring how well it prevented symptomatic COVID-19 infection seven days through up to six months after the second dose.

Efficacy in Delta variant

84% effective against delta flaps after two doses, and only 34% effective after the first dose